Why the study?
Does catheter ablation reduce levels of PAI-1 and CD40-L in patients with atrial fibrillation?
Cohort
Does catheter ablation reduce levels of PAI-1 and CD40-L in patients with atrial fibrillation?
Catheter ablation in patients with atrial fibrillation significantly reduces circulating levels of the inflammatory and prothrombotic biomarkers PAI-1 and CD40-L.
AF-associated CD40-L rise may reflect prothrombotic state; hypothesis-generating for ablation effects on biomarker modulation.
This study aims to examine the effects of atrial fibrillation (AF) on the expression of the cellular mediators plasminogen activator inhibitor 1 (PAI-1) and CD40 ligand (CD40-L). Additionally, the effect of catheter ablation on the levels of the aforementioned biomarkers was also examined. In this prospective study, plasma samples were collected from patients with AF at baseline prior to ablation and at 1 and 3 months postablation. There was a statistically significant increase in CD40-L at baseline in patients with AF compared to control ( P = .0034). There was a statistically significant decrease in CD40-L levels postablation at both 1 month ( P < .0001) and 3 months ( P < .0001) compared to baseline. Baseline levels of PAI-1 were elevated compared to the control group (mean 19.55 ± 2.17 ng/mL vs 4.85 ± 0.41 ng/mL) and a statistically significant decrease in circulating PAI-1 levels 1 month postablation ( P = .05) was noted compared to preablation levels. These data suggest that inflammation plays an important role in the pathogenesis of AF and that these cellular mediators are modulated by catheter ablation.
No takes yet. Share an insight, caveat, or question.
Otto et al. (2018) conducted a cohort in Atrial fibrillation. Catheter ablation vs. Baseline (preablation) and healthy controls was evaluated on CD40-L and PAI-1 levels (p=<.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: